Related Experiment Video

Updated: Oct 13, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

[Dapagliflozin in the prevention and treatment of heart failure]

I Egocheaga1, C Escobar2, V Pallarés3

  • 1Centro de Salud Isla de Oza, Madrid, España.

Semergen
|November 17, 2021
PubMed

Insights

Dapagliflozin significantly reduces hospitalization and death in heart failure (HF) patients with reduced ejection fraction. This treatment offers early benefits, improving quality of life regardless of diabetes status.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) involves complex neurohormonal systems.
  • Comprehensive therapeutic approaches targeting these systems are crucial for reducing mortality and hospitalizations.

Purpose of the Study:

  • To evaluate the efficacy of dapagliflozin in addition to standard treatment for HFrEF.
  • To assess the impact of dapagliflozin on cardiovascular death, HF hospitalizations, and overall mortality.

Main Methods:

  • The DAPA-HF trial investigated the effects of dapagliflozin in patients with HFrEF.
  • Standard treatment was augmented with dapagliflozin, and outcomes were compared to placebo.

Main Results:

  • Dapagliflozin significantly decreased the risk of cardiovascular death, HF hospitalization, and all-cause mortality.
  • Benefits were observed early in treatment and were consistent across patients with or without diabetes.
  • Functional class and quality of life were notably improved.

Conclusions:

  • Dapagliflozin is a key treatment for HFrEF, offering substantial prognostic benefits.
  • Early initiation of dapagliflozin provides significant advantages in managing HFrEF.
  • The drug's efficacy extends to diverse patient subgroups, including those without diabetes.

Keywords:
DAPA-HFDapagliflozinDapagliflozinaFracción de eyección reducidaHeart failureInsuficiencia cardiacaReduced left ventricular ejection fraction

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

837
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.0K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
291
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
48
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
340
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
567
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
301
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
475